Phase 3 Readout~month

Phase 3 Topline: An Open-label, Non-randomized, Multi-center Pivotal Phase 3 Study to Evaluate the Efficacy and Safet

Name: Phase 3 Topline: An Open-label, Non-randomized, Multi-center Pivotal Phase 3 Study to Evaluate the Efficacy and Safet
Start: 2027-06-01

June 1, 2027

Company: Insight Molecular Diagnostics Inc. (IMDX)
Indication: Alzheimer Disease

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: An Open-label, Non-randomized, Multi-center Pivotal Phase 3 Study to Evaluate the Efficacy and Safet — IMDX Phase 3 Readout | BioSniper